MA51309A - Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26 - Google Patents

Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26

Info

Publication number
MA51309A
MA51309A MA051309A MA51309A MA51309A MA 51309 A MA51309 A MA 51309A MA 051309 A MA051309 A MA 051309A MA 51309 A MA51309 A MA 51309A MA 51309 A MA51309 A MA 51309A
Authority
MA
Morocco
Prior art keywords
ligand
determining
biological activity
cellular process
quantitative cellular
Prior art date
Application number
MA051309A
Other languages
English (en)
Inventor
Naro Antonio Francesco Di
Original Assignee
Adienne S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adienne S A filed Critical Adienne S A
Publication of MA51309A publication Critical patent/MA51309A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • GPHYSICS
    • G06COMPUTING OR CALCULATING; COUNTING
    • G06FELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10Complex mathematical operations
    • G06F17/18Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mathematical Physics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Computational Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Toxicology (AREA)
  • Mathematical Optimization (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mathematical Analysis (AREA)
  • Organic Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • Probability & Statistics with Applications (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Algebra (AREA)
MA051309A 2017-12-22 2018-12-21 Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26 MA51309A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT201700148959 2017-12-22

Publications (1)

Publication Number Publication Date
MA51309A true MA51309A (fr) 2021-03-31

Family

ID=61868790

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051309A MA51309A (fr) 2017-12-22 2018-12-21 Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26

Country Status (22)

Country Link
US (1) US11959913B2 (fr)
EP (1) EP3729085B1 (fr)
JP (2) JP7366925B2 (fr)
KR (1) KR102747531B1 (fr)
CN (1) CN111433604B (fr)
AU (1) AU2018392227B2 (fr)
BR (1) BR112020012388A2 (fr)
CA (1) CA3085693A1 (fr)
DK (1) DK3729085T3 (fr)
ES (1) ES3056144T3 (fr)
FI (1) FI3729085T3 (fr)
HR (1) HRP20251577T1 (fr)
IL (1) IL275169B2 (fr)
LT (1) LT3729085T (fr)
MA (1) MA51309A (fr)
MX (1) MX2020006488A (fr)
PL (1) PL3729085T3 (fr)
PT (1) PT3729085T (fr)
RS (1) RS67591B1 (fr)
SI (1) SI3729085T1 (fr)
TW (1) TW201930880A (fr)
WO (1) WO2019123410A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092127A1 (fr) * 2001-05-11 2002-11-21 Board Of Regents, The University Of Texas System Therapie a base d'anticorps monoclonaux anti-cd26 contre des affections en lien avec des cellules exprimant le cd26
JP2008164325A (ja) * 2006-12-27 2008-07-17 Univ Of Tokyo 免疫調節剤のスクリーニング方法
AR084216A1 (es) * 2010-12-09 2013-05-02 Sanofi Sa Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
EP2767549A1 (fr) 2013-02-19 2014-08-20 Adienne S.A. Anticorps anti-CD26 et leurs utilisations
US9845345B2 (en) * 2015-05-18 2017-12-19 Ab Initio Biotherapeutics, Inc. SIRP polypeptide compositions and methods of use

Also Published As

Publication number Publication date
CN111433604B (zh) 2023-12-08
IL275169A (en) 2020-07-30
MX2020006488A (es) 2020-12-10
WO2019123410A1 (fr) 2019-06-27
FI3729085T3 (fi) 2025-12-19
EP3729085B1 (fr) 2025-11-05
ES3056144T3 (en) 2026-02-18
BR112020012388A2 (pt) 2020-11-24
CA3085693A1 (fr) 2019-06-27
KR20200103003A (ko) 2020-09-01
PL3729085T3 (pl) 2026-02-16
HRP20251577T1 (hr) 2026-02-27
DK3729085T3 (da) 2025-12-22
JP2024020200A (ja) 2024-02-14
KR102747531B1 (ko) 2024-12-27
TW201930880A (zh) 2019-08-01
CN111433604A (zh) 2020-07-17
AU2018392227A1 (en) 2020-07-09
US20200319169A1 (en) 2020-10-08
RU2020120500A (ru) 2022-01-24
RS67591B1 (sr) 2026-01-30
AU2018392227B2 (en) 2025-05-01
EP3729085A1 (fr) 2020-10-28
IL275169B2 (en) 2025-06-01
PT3729085T (pt) 2025-12-22
JP7529373B2 (ja) 2024-08-06
US11959913B2 (en) 2024-04-16
IL275169B1 (en) 2025-02-01
JP7366925B2 (ja) 2023-10-23
SI3729085T1 (sl) 2026-02-27
LT3729085T (lt) 2026-01-26
JP2021508834A (ja) 2021-03-11

Similar Documents

Publication Publication Date Title
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
EP3267995A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose
EP3492462A4 (fr) Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase
EP3384070A4 (fr) Procédé d'amélioration de l'activité catalytique
EP3397968A4 (fr) Inhibiteurs de l'antigène membranaire spécifique de la prostate (psma) à base d'urée, pour imagerie et traitement thérapeutique
EP3349729A4 (fr) Support stériquement stabilisé pour agents thérapeutiques sous-cutanés, sublinguaux et oraux, compositions et procédés pour le traitement d'un mammifère
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
EP3447137A4 (fr) Préparation d'enzyme liquide et son procédé de préparation
MA52545A (fr) Anticorps pour radionucléides chélatés
EP3604515A4 (fr) Composition pour la production de tagatose et procédé de production de tagatose l'utilisant
EP3409108A4 (fr) Couvre-lit pour lit d'animaux de compagnie
EP4045036C0 (fr) Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1
EP3975693A4 (fr) Unité de production pour la culture ou la propagation d'organismes
EP3819284A4 (fr) Catalyseur pour la préparation de 1,2-pentanediol et procédé de préparation de 1,2-pentanediol l'utilisant
EP3509594C0 (fr) Inhibiteur d'homologue 2 de lysyl-oxydase pour son employ dans le traitement de la myélofibrose
EP3606520A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
EP3852617A4 (fr) Procédés de réversion d'activité de ticagrélor
EP3553057A4 (fr) Composé (hétéro)arylamide pour inhiber l'activité de la protéine kinase
EP3968989A4 (fr) Composé pour le traitement de la goutte ou de l'hyperuricémie
EP3466542A4 (fr) Cuve pour centrifugeuse et procédé d'isolation de svf utilisant celle-ci.
MA53501A (fr) Inhibiteurs de pde9 pour le traitement de la drépanocytose
EP3426254A4 (fr) Utilisation d'inhibiteurs de braf pour le traitement de réactions cutanées
EP3844171A4 (fr) Amplificateurs de l'activité de la neurolysine
MA53014A (fr) Composés améliorant l'activité du protéasome
EP3859332A4 (fr) Procédé de dosage d'hémoglobine glyquée (%)